FDA Adds New INCI Codes for Plant Stem Cell Extracts

On April 23, 2026, the U.S. Food and Drug Administration (FDA) updated its Cosmetic Ingredient Dictionary to assign dedicated INCI codes to plant stem cell extracts—including those derived from apple, grape, and ginseng—and introduced mandatory documentation requirements for import declarations. This update directly affects cosmetic ingredient suppliers, contract manufacturers, importers, and brand owners operating in or exporting to the U.S. market, as non-compliant submissions now trigger automatic rejection and shipment return.

Event Overview

On April 23, 2026, the FDA revised the Cosmetic Ingredient Dictionary to establish distinct INCI (International Nomenclature of Cosmetic Ingredients) codes specifically for plant stem cell extracts. The update applies to extracts sourced from plants such as apple, grape, and ginseng. Concurrently, the FDA mandated that all import declarations for such ingredients must include: (1) the botanical variety of the source plant; (2) the tissue culture passage number; (3) the method used to induce cellular differentiation; and (4) a sterility validation report. Submissions lacking any of these documents will be classified as ‘unreported new ingredients’ and subject to refusal and return.

Impact on Specific Industry Segments

Direct Trade Enterprises (e.g., U.S. importers, export agents)
These entities are responsible for customs filing and regulatory compliance at the point of entry. Under the new rule, they must verify and submit technical documentation before clearance—adding verification steps and potential delays. Failure to provide complete documentation results in immediate shipment rejection, increasing logistics risk and cost exposure.

Raw Material Sourcing Companies (e.g., ingredient distributors, specialty suppliers)
Suppliers of plant stem cell extracts must now generate and maintain standardized technical dossiers for each batch or product line. The requirement for documented plant variety, passage number, differentiation method, and sterility validation means existing quality records may be insufficient—requiring internal process alignment with FDA expectations.

Contract Manufacturing & Formulation Facilities
Manufacturers using plant stem cell extracts in finished cosmetics must ensure full traceability upstream. If sourcing from third-party suppliers, they bear responsibility for verifying that submitted documentation meets FDA criteria—especially where private-label or white-label arrangements obscure ingredient provenance.

Supply Chain Service Providers (e.g., regulatory consultants, testing labs, certification bodies)
These providers face increased demand for support in dossier preparation, sterility method validation, and botanical identification services. However, no official FDA guidance or reference standards have yet been published to define acceptable methods for passage number tracking or differentiation verification—creating interpretive ambiguity.

What Relevant Companies or Practitioners Should Focus On and Do Now

Monitor official FDA communications for implementation clarifications

The FDA has not yet issued formal guidance on how ‘tissue culture passage number’ or ‘induced differentiation method’ should be defined or reported. Stakeholders should track updates from the FDA’s Center for Food Safety and Applied Nutrition (CFSAN) and subscribe to its Cosmetic Regulatory Updates mailing list.

Review current inventory and supplier documentation for high-priority extracts

Companies should identify which plant stem cell-derived ingredients—especially apple, grape, and ginseng extracts—are already in use or planned for U.S.-bound products. For each, assess whether existing supplier data covers all four required elements. Gaps should be flagged for immediate follow-up with suppliers.

Distinguish between policy signal and operational enforcement

Analysis shows this is a structural update to the INCI dictionary—not a newly proposed regulation. It signals FDA’s intent to treat plant stem cell extracts as distinct, traceable entities rather than generic botanicals. However, enforcement timelines, inspection protocols, and penalties for partial noncompliance remain unannounced.

Prepare documentation templates and internal review workflows

Develop standardized internal checklists and submission templates aligned with the four required data points. Assign responsibility across R&D, QA, and regulatory affairs teams to avoid bottlenecks during customs filing. Where possible, request advance documentation from suppliers ahead of shipment scheduling.

Editorial Perspective / Industry Observation

Observably, this update reflects a broader regulatory shift toward granular traceability for biotechnologically derived cosmetic ingredients. It does not introduce new safety requirements per se, but elevates documentation rigor to match the complexity of plant cell culture processes. From an industry perspective, it functions less as an immediate compliance deadline and more as a formal recognition that plant stem cell extracts fall outside traditional botanical ingredient frameworks. Current attention should focus on documentation readiness—not reformulation—since no safety or labeling thresholds were altered. Continued observation is warranted for future FDA guidance on analytical verification methods and whether similar requirements extend to other cultured-plant ingredients.

As of publication, this change is effective immediately under the updated Cosmetic Ingredient Dictionary. No transitional period or grace period has been announced.

Conclusion
This FDA update establishes a foundational classification and documentation framework for plant stem cell extracts in U.S. cosmetics regulation. It does not ban or restrict use, nor does it alter safety assessment pathways—but it does require precise, verifiable traceability from plant variety through cultivation. For stakeholders, the most pragmatic interpretation is that this is a procedural calibration, not a substantive barrier—provided documentation systems are aligned proactively.

Source Attribution
Main source: U.S. FDA, Cosmetic Ingredient Dictionary, updated April 23, 2026.
Note: Implementation details—including accepted formats for sterility validation, definitions of ‘passage number’, and enforcement frequency—remain pending official clarification and are subject to ongoing monitoring.